The treatment with a ligand of Transcriptional Factor improves sepsis survival through anti-inflammatory effects
Project/Area Number |
18591979
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Emergency medicine
|
Research Institution | Tokyo Medical and Dental University |
Principal Investigator |
ISOBE Mitsuaki Tokyo Medical and Dental University, Graduate school of medicine, Department of Cardiovascular Medicine, professor (80176263)
|
Co-Investigator(Kenkyū-buntansha) |
HARAGUCHI Go Tokyo Medical and Dental University, Division of Cardiovascular Medicine, assistant professor (40361729)
|
Project Period (FY) |
2006 – 2007
|
Project Status |
Completed (Fiscal Year 2007)
|
Budget Amount *help |
¥1,550,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥150,000)
Fiscal Year 2007: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2006: ¥900,000 (Direct Cost: ¥900,000)
|
Keywords | Sepsis / Transcriptional Factor / Apolipoprotein E / Anti-inflammatory effects / PPAR / 集中治療 / 敗血症性ショック / ピオグリタゾン |
Research Abstract |
Objective: Septic shock is the most common cause of death in intensive care unit next to cardiovascular diseases. Unfortunately, no effective treatment for this condition currently exists. Peroxisome proliferator-activated receptor (PPAR)-_Yligands are reported to reduce inflammatory responses. To evaluate the hypothesis that PPAR-_Yligands improve survival of septic shock, a mouse model of sepsis (apolipoprotein E (ApoE) knockout) was used and treated with pioglitazone, a PPAR-_Yligand. ApoE knockout mice have high mortality rate in sepsis due to lack of endotoxin clearance. Design and settings; Prospective laboratory study in a university laboratory. Subjects: Total 72 male ApoE knock out mice and 60 wild type C57/B6 mice randomized into three groups (sepsis, pre-treatment, post-treatment). Interventions; Cecal ligation and puncture were done in the sepsis and treatment groups. Mice injected with pioglitazone (5mg/kg/day) on the day before operation or mice injected with pioglitazone 6 hours after operation. Measurements and Main Results: Both pre- and post- operation treatment of pioglitazone improved survival of mortality in ApoE knock out and wild type mice. Serum levels of cytokines and chemokines, myeloperoxidase activity of lung and liver showed the same suppression in pioglitazone treatment group. Pioglitazone also suppressed monocytes adhesion to vascular endothelium under flow condition. Conclusions: Pioglitazone improved survival rate of apoE knockout mice after onset of septic shock through suppression of inflammatory respon
|
Report
(3 results)
Research Products
(3 results)